At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Finasteride 5 mg tablets +1 moredrug
Likely dose
Finasteride 5 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Finasteride 5 mg tablets and PROSCAR® for Healthy. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The objective of this study is to compare the relative bioavailability of finasteride 5 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of PROSCAR® 5 mg tablets (Merck) in healthy, adult, non-smoking, male subjects under fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2002
Primary CompletionJun 2002
First PostedFeb 2009
TodayJul 2026
First PostedFeb 4, 2009
Enrollment StartJun 1, 2002
Primary CompletionJun 1, 2002
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago
Interventions
Finasteride 5 mg tabletsdrug
1 x 5 mg, single dose fasting
PROSCAR®drug
1 x 5 mg, single dose fasting